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Abstract
Prion diseases are invariably lethal neurodegenerative diseases, associated with the 
structural conversion of the cellular isoform of the prion protein to its pathological, dis-
ease-associated isoform. The cellular isoform of the prion protein is highly conserved and 
virtually ubiquitously expressed; nevertheless, its physiological role remains unclear. 
Mounting evidence suggests its involvement in the regulation and function of the 
immune system. At the same time, the immune system is heavily involved in the patho-
genesis of the diseases, playing a major role in the peripheral replication of the infectious 
agent and spread toward the central nervous system. On the other hand, immunothera-
pies are among the most promising means of intervention. This chapter deals with these 
fascinating and sometimes contrasting aspects of prion biology, with an emphasis on 
the immunization protocols developed for prophylaxis and treatment of prion diseases.
Keywords: prion, immunobiology, active immunization, passive immunization, DNA 
vaccines, mucosal vaccination
1. Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases are invariably lethal 
neurodegenerative diseases afflicting a wide variety of species, including humans [1]. The 
common pathogen to all TSEs is termed prion and is believed to consist solely or primarily 
of the disease-associated isoform (PrPSc) of the cellular prion protein (PrPC). PrPC is a highly 
conserved, GPI-anchored sialoglycoprotein encoded by the single-copy Prnp gene. Prnp is 
virtually ubiquitously expressed, with its expression peaking in the neuronal tissue, whereas 
high Prnp expression levels have been reported in many cells of the immune system. PrPSc is 
believed to propagate by inducing the conformational conversion of PrPC molecules into new 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
PrPSc copies. The exact mechanism governing this conversion is still under dispute, but it is 
widely accepted that it does not involve modifications of the primary structure of the protein.
The physiological and pathological PrP isoforms display distinct conformations. The 
N-terminal region of PrPC is highly unstructured, as opposed to the globular C-terminal 
region, which contains predominantly a-helices and only a minor region encompassing two-
stranded β sheet [2]. Infrared spectroscopy and circular dichroism data indicate clear differ-
ences in the secondary structure of PrPC and PrPSc, in which equal amounts of a-helices and 
β sheets can be found [3]. This conformational difference is believed to be at the basis of the 
biochemical differences observed between the two isoforms, namely, the partial proteinase K 
resistance, the reduced solubility, and the fibril-producing potential displayed by PrPSc [4]. To 
date, the only known difference at the chemical level is associated with the oxidation level of 
the methionine residues, which was found to be elevated in PrPSc compared to PrPC [5].
The physiological role of the prion protein remains obscure. Its high level of conservation 
among species would indicate that PrPC is of crucial importance to the organism; however, 
PrP−/− mice are viable, developmentally and behaviorally normal, and do not display a promi-
nent phenotype except for the complete protection against prion diseases [6, 7]. PrPC has 
since been implicated in a variety of cellular functions, including cell proliferation, differ-
entiation and survival, protection against oxidative stress, and synaptic function (reviewed 
in [8, 9]). Further evidence suggests it may play a role in the immune system. In line with 
this, it has been recently reported that PrP−/− mice display lower numbers of CD4 T cells 
and lymphoid tissue inducer (LTi) cells as well as impaired splenic T zone structures [10]. 
Moreover, immune responses have been reported during prion diseases progression, sug-
gesting the involvement of the immune system in disease pathogenesis, and immune-based 
approaches have yielded some of the most promising results toward protection and/or treat-
ment of spongiform encephalopathies. In this chapter these exciting aspects of prion biology 
will be discussed.
2. PrP and the immune system
2.1. PrPC expression patterns in cells of the immune system
Even though PrPC is predominantly expressed in the central and peripheral nervous system 
[11, 12], elevated protein expression levels have also been reported in many cells of the immune 
system. In long-term hematopoietic stem cells (HSCs), PrPC expression levels are raised and 
PrPC has been suggested as a marker for these cells [13]. PrPC expression is retained through-
out maturation either toward the myeloid [14] or the lymphoid lineage [15, 16]. Interestingly, 
along the granulocyte maturation lineage, PrPC expression is downregulated [17].
Among cells of the lymphoid lineage, T cells, monocytes, and natural killer (NK) cells express 
higher PrPC levels compared to B lymphocytes [18]. PrPC expression levels are regulated 
and can vary greatly across different T-cell subtypes: CD8+ cells display higher expression 
levels than CD4+ cells, and between CD4+ cells, CD25+ expresses 4.5-fold higher Prnp lev-
els than CD25− cells [19], while CD45RO+ memory T lymphocytes express higher PrPC levels 
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 compared to naïve CD45RA+ T lymphocytes [16]. It would thus appear that PrPC expression 
levels in cells of the immune system are dynamic, indicating that PrPC may play a role in the 
immune system.
2.2. PrPC function in the immune system
Despite evidence that PrPC may be associated with the function of the immune system, its 
role remains unclear. PrP−/− mice do not display gross overt effects, at least under normal 
conditions. However, evidence indicates that when PrP−/− mice are subject to immunological 
stress their phenotype may deviate from normal. To test whether PrPC may act as a regula-
tor of cellular immunity, the effect PrPC deficiency may have on the course of experimental 
autoimmune encephalomyelitis (EAE) was assessed [20]. EAE is an inflammatory demyelin-
ating disease of the central nervous system (CNS), triggered by the injection of brain extracts, 
proteins of the CNS such as the myelin basic protein and the myelin oligodendrocyte glyco-
protein (MOG) or peptides from these proteins to experimental animals, usually mice and 
rats. EAE is widely used as an animal model for multiple sclerosis and acute disseminated 
encephalomyelitis but is also considered the prototype for T-cell–mediated autoimmune 
disease in general [21]. It was found that PrP−/− mice displayed a more aggressive disease 
onset and no clinical improvement during the chronic phase of the disease. These clinical 
findings were in agreement with the increased cytokine gene expression in MOG-primed 
PrP−/− cells and indicate that PrPC could be involved in the attenuation of T-cell-dependent 
neuroinflammation.
Similar results were obtained when Prnp expression was silenced via treatment with small 
interfering ribonucleic acid (siRNA) targeting Prnp. In this case, siRNA administration led to 
effective Prnp silencing in the lymphoid tissue, but not the central nervous system. In agree-
ment to the results obtained with PrP−/− mice, siRNA-mediated Prnp silencing led to marked 
worsening of EAE [22]. In a series of elegant experiments, it was shown that the central ner-
vous system autoimmune disease was modulated at all stages of the disease and that PrPC 
regulates activation of T lymphocytes mediated by the T-cell receptor (TCR), differentiation, 
and survival, thus identifying PrPC as a regulator of cellular immunological homeostasis. 
The proposed immunomodulatory properties when considered in conjunction with (i) the 
protein’s expression patterns, which overlap with immune-privileged organs and (ii) the 
observation that only minor phenotypes can be associated with PrP−/− mice under physiologi-
cal conditions, but rather striking ones under stress and particularly under inflammation in 
immune-privileged organs, has led to the hypothesis that PrPC may be involved in immune 
quiescence, protecting immune-privileged organs, such as the brain [23].
3. Prion disease pathogenesis and the immune system
The central event in the pathogenesis of all forms of transmissible spongiform encephalopa-
thies is the conversion of PrPC to the more thermodynamically stable PrPSc by PrPSc via a 
mechanism which remains at large obscure [24]. Regrettably, the actual conversion mecha-
nism is not the only missing piece of the prion disease pathogenesis puzzle, and not much is 
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known on how the infectious agent enters the host or how it is transported from the periphery 
to the central nervous system. A series of experiments using animal models of TSEs have pro-
vided interesting data on pathogenesis.
Parenteral—usually intracranial or intraperitoneal—administration of the pathogen to hamsters 
or mice is among the most widely used animal TSE models. Such models are particularly useful, 
since most of the naturally acquired TSE cases both in humans and animals are contracted via 
peripheral—through the alimentary tract—exposure to the pathogen [25]. While these models 
provide a wealth of information regarding pathogenesis, it later became evident that different 
mechanisms are involved in the pathogenesis of prion infection following the intraperitoneal or 
the oral route of infection [26], and other factors such as the pathogen strain and the host spe-
cies and/or strain can also have a major impact on the mechanisms involved [27]. For example, 
in a recent study in sheep with different Prnp polymorphisms, which confer different levels of 
resistance to prion infection, it was observed that following intracranial administration of the 
pathogen, sheep with a “resistant” genetic polymorphism did not accumulate the pathogen in 
lymphoid tissues [28]. Even more strikingly, it has recently been reported that the role of the 
immune system might be limited in case of genetic prion disease. In a murine model of late 
onset genetic Creutzfeldt-Jakob disease, PrPSc has not been detected in the lymph nodes or the 
spleens of the transgenic mice at all ages and stages of disease, indicating that in this case con-
version of PrPC to PrPSc occurs predominantly or even exclusively within the CNS [29].
Prion pathogenesis can be divided into phases, some of which may take place in parallel: (i) 
peripheral prion exposure and uptake, (ii) peripheral pathogen replication, (iii) migration 
through the peripheral nervous system to the CNS, and (iv) centrifugal spread from the CNS 
back to the periphery [25, 27]. Despite PrPSc can be detected in various sites following periph-
eral exposure, especially in the lymphatic system, signs of pathology, including neurodegen-
eration, spongiosis, and gliosis are only found within the CNS. It is important to stress that as 
the means available evolve, our understanding of the phenomena taking place also improves. 
For instance, detection of PrPSc in the brains of some peripherally challenged hamsters as 
early as 4 and 9 days following challenge was recently reported [30].
M cells, which are epithelial cells specialized for transepithelial transport found in the follicle-
associated epithelia of the small and large intestines, tonsils and adenoids [31], were shown 
capable of transcytosing the TSE infectious agent in vivo [32]. In addition to M cells, other 
epithelial cells may be involved in the uptake of the pathogen in a ferritin-mediated mecha-
nism [33]. The pathogen is first detected in gut-associated lymphoid tissue (GALT), including 
Peyer’s patches and mesenteric lymph nodes [26]. Evidence from in vitro studies indicates 
that the GALT in the small rather than the large intestine plays a major role in PrPSc accumula-
tion and eventually neuroinvasion [34].
It is not yet clear how the pathogen is transported from the entry site to the lymphoid tissue. It 
has been hypothesized that following pathogen uptake by M cells, the infectious agent can be 
transported to the M cells’ intraepithelial pocket, where it can be processed by macrophages, 
B- and T- lymphocytes residing within this pocket or the dendritic cells, macrophages, and 
lymphocytes situated immediately beneath the intraepithelial pocket [35]. Of these cells, mac-
rophages and dendritic cells appear the most plausible candidates for effective transport of 
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the pathogen. In line with this assumption, PrP accumulations were detected in various types 
of macrophages following TSE infection [36–38]. However, the role macrophages undertake 
remains obscure, as in vivo experiments have shown that macrophages may also be involved 
in clearing the pathogen [39, 40]. It seems that the role of the macrophages following prion 
infection depends on the infectious dose and the agent strain [41]. Macrophages may also 
be important for the delivery of the infectious agent to the neural cells, and in this case, cell 
death may play an important role. In recent in vitro studies, it was determined that coculture 
of killed, PrPSc-infected macrophages with N2a-3 neuroblastoma cells accelerated PrPSc trans-
mission to the neuronal cells [42]. Dendritic cells on the other hand can be ideally located to 
transport the pathogen following uptake by the M cells, and some of them have already been 
shown to be able to transport PrPSc without degrading it [43, 44].
B lymphocytes were initially identified as the cells involved in replication of the TSE infec-
tious agent [45], but this hypothesis was later revised, and the role of B lymphocytes in prion 
pathogenesis was associated with the regulated maturation of follicular dendritic cells (FDCs) 
[46]. Initial experiments with splenectomized or thymectomized mice indicated the dispens-
able role of T lymphocytes in the replication of the agent [47], whereas fractionation [48] and 
irradiation [49] experiments indicated that replication of the pathogen depends on radiore-
sistant cells, localized within the stromal compartment of the spleen. FDCs fulfill all these 
criteria, and their crucial role for replication of the pathogen was confirmed in a series of 
experiments, in which depletion of mature FDCs led to prolongation of the incubation period 
of the disease [46, 50–53]. FDCs are of stromal origin, reside in the primary B lymphocytes fol-
licles and germinal centers of lymphoid tissues, and are non-phagocytic and non-migratory. 
As a result of their large surface area and longevity, FDCs are capable of trapping and retain-
ing antigen in its native state for months to years. FDCs retain antigens in the form of immune 
complexes, consisting of antigen-complement components and/or antibody and trap these 
complexes either through complement receptors CR1 and CR2 or through FcRIIb and FcεRII 
antibody receptors [35]. In agreement with the role FDCs undertake in prion pathogenesis 
and the involvement of complement components and receptors in antigen trapping by FDCs, 
it was found that the absence of complement components (C1q, C2, C3, and factor B) and 
cellular complement receptor can have an adverse effect on the accumulation of PrPSc in the 
spleen [54, 55]. However, the inability to completely inhibit disease progression via depletion 
of mature FDCs [46, 51], in addition to observations confirming that propagation of prion 
diseases is possible even in the absence of mature FDCs [41, 56–58], indicates that possibly a 
different cell type—most probably MOMA-1-positive macrophages [41]—is responsible for 
replication of the pathogen. These differences in the cell types required for pathogenesis were 
attributed to the dose and agent strain [41].
Peripheral replication of the pathogen precedes neuroinvasion, during which the pathogen 
is transported within the CNS. Both the enteric and autonomic nervous systems are believed 
to participate in the transport of the infectious agent [36, 59, 60]. The exact mechanism gov-
erning transport of the pathogen to the CNS remains unidentified, and has been reported to 
be both PrPC-dependent [61, 62] and independent [63]. Interestingly, it was reported that the 
transfer speed of intraperitoneally administered prions relies to the distance between FDCs 
and splenic nerve endings [64, 65].
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The immune system is greatly implicated in the peripheral pathogenesis of prion diseases 
but fails to provide protection. Until recently, no response against the prion pathogen has 
been described, and this was linked to tolerance effects due to widespread expression of the 
physiological isoform of the prion protein throughout the body, which prevents the host from 
mounting a humoral or cellular immune response against PrPSc following infection [66]. On 
the contrary, PrP−/− mice mount a robust immune response against PrP, indicating the immu-
nogenicity of the protein. Lately it was shown that TSE infection can have adverse effects on 
the maturation cycle of FDCs, causing an abnormality in immune function [67]. Given the cru-
cial role the immune system plays in the peripheral pathogenesis of prion diseases, it could 
be argued that it promotes rather than protects against prion pathogenesis. In agreement with 
this, increased susceptibility to intraperitoneal challenge with TSE agents following repetitive 
immunization was recently reported [68].
4. Harnessing the immune system against prion diseases
Since the immune system plays an ambivalent role in prion disease pathogenesis, the question 
emerged whether suppressing the immune system would be the most appropriate approach 
[69]. Targeting the FDCs was already proven a viable approach, providing partial protection 
in an animal model of prion diseases and minimizing the infectivity of the peripheral tissue 
of the afflicted animals [46, 50–52]. Disruption of the FDCs also appears to be the protective 
mechanism against TSEs following repetitive CpG administration [70]. CpG had previously 
been administered as a stimulator of innate immunity and was shown effective at provid-
ing partial protection in an animal model of TSEs [71]. In this case CpG was administered 
to stimulate the macrophages and enhance phagocytosis of the pathogen. Indeed, repetitive 
administration provided partial protection against TSEs [71], but as it was later shown, this 
protection was due to disruption of the lymphoid follicles rather than stimulation of the mac-
rophages [70]. Interestingly, disruption of the FDCs has also been observed following immu-
nization of wild-type mice with recombinant murine PrP aggregates and is at least in part 
responsible for the observed partial protection when the immunized mice were challenged 
with a murine strain of TSEs [72].
The first indications that the immune system might prove effective against prion diseases 
stemmed from in vitro experiments, where it was shown that treatment of TSE-infected cell 
cultures with monoclonal anti-PrP antibodies could effectively inhibit PrPSc replication and 
on some occasions clear infectivity [73–75]. Proof of principle that immunization against 
prion diseases can be effective against prion diseases was provided later using transgenic 
mice, capable of producing anti-PrP antibodies. These mice, in contrast to wild-type controls, 
failed to succumb to disease following challenge with a mouse-adapted scrapie strain [76]. 
Similarly, passive immunization of wild-type mice, by administration of anti-PrP antibodies 
was found to provide protection against prion diseases [77].
From this initial series of experiments, valuable conclusions emerged, most importantly, that 
immunization is an efficient means of therapy rather than protection, against prion diseases. 
Moreover, the safety of these procedures was confirmed, since immunization against a self-
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antigen could always give rise to autoimmunity. Given the identical primary structure PrPC 
and PrPSc share, adverse reactions stemming from the reaction of the anti-PrP antibodies with 
PrPC could be expected. Autoimmunity was not induced by these immunization approaches, 
and furthermore the “dispensable” role of the prion protein for the appearance of a physi-
ological phenotype was already known from studies on PrP-/- animals [6], as well as from 
transgenic animals with conditional depletion of the prion protein [78] and provided an extra 
layer of security. However, other findings raised some concerns over the safety of administra-
tion of anti-PrP antibodies, since it was found that intracerebral administration of anti-PrP 
monoclonal antibodies can give rise to cross-linking of PrP molecules on adjacent neurons 
and eventually cell death, triggered possibly by the initiation of death signaling [79]. These 
effects are clearly not associated with autoimmunity, but rather with impaired cell signaling.
4.1. Passive immunization approaches
The first indications that passive immunization could prove useful at protecting against prion 
diseases emerged from studies in which mice genetically modified to produce an anti-PrP 
monoclonal antibody (6H4μ) were fully protected against prion diseases [76]. In a more clas-
sical approach, monoclonal anti-PrP antibodies (ICSM18 and ICSM35) were administered 
intraperitoneally to wild-type mice briefly after intraperitoneal inoculation with the patho-
gen or when the first clinical signs appeared. When the antibodies were administered after 
the inoculation, animals receiving the antibodies survived approximately 300 days more 
than control mice, and the accumulation of infectivity in the peripheral tissue was markedly 
reduced [77]. Intraperitoneal administration of a different antibody (6D11) immediately after 
intraperitoneal administration of the pathogen also proved its protective efficacy, since mice 
receiving the antibody survived longer by approximately 36.9% compared to control mice. In 
a recent study, a pharmacokinetic and pharmacodynamic analysis following intraperitoneal 
administration of various anti-PrP antibodies was carried out. The ability of an antibody to 
form long-lasting complexes with PrPC was found to positively correlate with its efficacy in 
delaying peripheral accumulation of PrPSc and, in agreement with this, intraperitoneal admin-
istration of the monoclonal antibody BAR216 led to a statistically significant prolongation of 
survival of the mice [80].
The therapeutic efficacy of intracerebral administration of anti-PrP monoclonal antibod-
ies was evaluated in two recent studies. In the first one, monoclonal antibody 4H11 (F(ab′)
2
 
and IgG) was intraventricularly administered to transgenic mice overexpressing PrP using 
osmotic pumps from d85 to d100 following intraperitoneal challenge with a mouse-adapted 
bovine spongiform encephalopathy (BSE) strain. The mice were not protected by this regi-
men, and they succumbed to disease concomitantly with the control mice. Furthermore, mice 
treated with the antibodies developed neuronal cell death, associated with administration of 
the antibodies. In addition to previously reported results [79], linking cell death to PrP cross-
linking events, in this study, emerged that PrP cross-linking is not the only mechanism medi-
ating cell death; “coating” the whole cell surface PrP with antibodies or antibodies fragments 
could induce other toxic signals [81]. In the second study, intraventricular administration of 
antibodies 106, 110, 31C6, and 44B1 to wild-type mice was not linked with neuronal cell death; 
however, only a minor prolongation of survival and in one of the two tested animal models 
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was achieved following administration of the monoclonal antibodies [82]. Differences in the 
epitopes recognized by the antibodies used in these two studies as well as the use of PrP over-
expressing versus wild-type mice could account for the different results obtained regarding 
neuronal cell death. Of note, neuronal cell death has been challenged in another, more recent 
study, and it would be safe to assume that toxic effects are associated with the epitope and the 
dosage of the antibodies used [83].
A completely different passive immunization approach was used in two other studies; based 
on the discovery of the non-integrin 37/67 kDa lamin receptor (LRP/LR) as an interaction 
partner for both isoforms of PrP [84–86], polyclonal anti-LRP/LR [87] or single-chain Fv anti-
LRP/LR antibodies [88] were intraperitoneally administered to wild-type mice as protective 
means in a mouse model of prion diseases. On both occasions, peripheral PrPSc accumulation 
was reduced; however, partial protection was only achieved with the polyclonal antibodies. 
This difference in the efficacy was attributed to differences in the pharmacokinetics and dos-
age regimen; polyclonal antibodies have a half-life of approximately 14 days in the blood, 
whereas the single-chain antibodies have a half-life of only 12 h. Moreover, the polyclonal 
antibodies were administered for 12 weeks, starting 1 week before administration of the 
pathogen, whereas the single-chain antibodies for 8 weeks. Passive immunization approaches 
are summarized in Table 1.
4.2. Active immunization approaches
Although passive immunization does protect against prion diseases, it provides a narrow 
window for intervention, i.e., antibodies must be administered shortly after exposure to the 
pathogen. In this regard, active immunization against the prion protein, which provides pro-
tection against the diseases similarly to a conventional vaccine, could prove a much more 
useful approach. Nevertheless, the prion protein-associated tolerance effects which prevent 
the immune system from mounting an immune response against the prion protein hinder 
development of such approaches [66].
Despite the tolerance effects, initiation of a humoral immune response against the prion pro-
tein was achieved, albeit with mediocre results in terms of protection against the disease. 
In the first reports, wild-type mice were immunized with recombinant murine prion pro-
tein mixed with complete Freund’s adjuvant (CFA) and challenged with a mouse-adapted 
scrapie strain either concomitantly with the immunization (rescue treatment) or following 
its completion (prophylactic treatment). Although the mice developed antibodies against the 
prion protein, only mice of the prophylactic treatment group were partially protected against 
the pathogen; mice of this group succumbed to disease with a delay of approximately 16d 
compared to control mice [89].
4.2.1. Peptide-based active immunization
Numerous strategies were implemented to overcome the tolerance effects and promote gen-
eration of anti-prion antibodies. The most obvious approach was to use prion peptides prop-
erly modified to enhance the antigenicity of the protein (summarized in Table 2). Following 
this rationale, wild-type animals were immunized with prion protein peptides [90–93], PrP 
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Antibody 
name
Antibody 
type and 
target
Epitope Administration protocol In vitro assay In vivo assay Reference
ICSM18, 
ICSM35
Monoclonal, 
PrP
ICSM18: 
143–153aa
ICSM35: 
93–105aa
Intraperitoneal 
administration twice 
weekly starting 7 or 30 days 
after administration of the 
pathogen or at onset of the 
clinical symptoms
NP Prolonged survival 
interval in a mouse 
model of prion 
disease when the 
antibodies were 
administered prior 
to the appearance of 
clinical symptoms
[77]
6D11 Monoclonal, 
PrP
97–110aa One intravenous 
administration immediately 
after administration of 
the pathogen followed by 
consecutive intraperitoneal 
administrations (twice per 
week for 4 or 8 weeks)
Prevention of 
infection and 
clearance of 
infection in 
already prion-
infected cell 
lines
Prolongation of 
incubation period 
in a mouse model of 
prion disease
[115]
BAR236 Monoclonal, 
PrP
Linear epitope 
unidentified
Intraperitoneal (3 weekly 
administrations, starting 1 
week after administration 
of the pathogen)
NP Prolongation of 
survival interval in 
a mouse model of 
prion disease
[80]
4H11 Monoclonal 
or F(ab′)
2
 
fragments, 
PrP
Epitope within 
octarepeat 
region 
(59–89aa)
Intraventricular (osmotic 
pump delivering antibody 
for 16 days starting 85 days 
after administration of the 
pathogen)
Inhibition 
of PrPSc 
propagation  
in an already 
prion-infected 
cell line. 
Recognition of 
PrP on the cell 
surface by FACS
Intraventricular 
administration of 
the antibody did not 
prolong survival 
interval in a mouse 
model of prion 
disease
[81]
106, 110, 
31C6, 
44B1
Monoclonal, 
anti-PrP
106: 88–90aa
110: 83–89aa
31C6: 
143–149aa
44B1: 
discontinuous 
epitope within 
aa 155–231 aa
Intraventricular (osmotic 
pump delivering antibody 
for 14 days starting 60, 
90, or 120 days after 
administration of the 
pathogen)
NP Small (8%) 
prolongation of 
survival interval in 
a mouse model of 
prion diseases, even 
when administration 
of antibodies 
commences after 
appearance of first 
symptoms (120 days 
after administration 
of the pathogen)
[82]
pAb W3 Polyclonal 
anti-LRP/LR
Undefined Intraperitoneal (12 weekly 
administrations starting 1 
week before administration 
of the pathogen)
NP Prolongation of 
survival interval, but 
not of incubation 
period in a mouse 
model of prion 
disease
[87]
S18 scFV, LRP 272–280aa Intraperitoneal (8 weekly 
administrations starting 1 
day before administration 
of the pathogen)
S18 prevents 
interaction of 
the recombinant 
human PrP with 
recombinant 
human LRP
Reduction of 
splenic PrPSc, but 
no prolongation of 
survival interval in 
a mouse model of 
prion disease
[88]
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dimers [94–96], or PrP aggregates [72]. In addition to homologous prion protein immuni-
zation [89], which provided proof of principle that active immunization can have a pro-
tective role against prion diseases, immunization with heterologous prion peptides also 
provided rather encouraging results [97]. In an attempt to enhance the immunogenicity of 
the prion peptides, various adjuvants, including Freund’s adjuvant, Montanide IMS-1313, 
TiterMax, CpG, anti-OX40 antibodies—antibodies against the signaling molecule CD134, 
which recently has been shown to break T cell tolerance—and keyhole limpet hemocyanin, 
were used [95, 98], as well as different vaccine formulations, including encapsulation of the 
CpG-antigen complex in polylactide-coglycolide microspheres [96]. Interestingly, an early 
report indicates that immunization with complete Freund’s adjuvant alone can provide par-
tial protection in a mouse model of prion diseases through an unidentified mechanism [99]. 
Based on the extremely strong adjuvant effect exerted by heat-shock proteins, PrP molecules 
chemically cross-linked [100] or fused [72] to recombinant bacterial heat-shock proteins were 
also used to immunize wild-type mice and lead to the production of antibodies that recog-
nized recombinant PrP.
Despite the widely accepted notion that PrPSc is not immunogenic and that the immune 
system does not provide protection against PrPSc in wild-type animals, when highly puri-
fied proteinase K-resistant PrPSc, originating from murine brains afflicted with an animal 
model of prion diseases was coadministered with CpG [101] or administered immobilized 
on Dynabeads coated with antibodies against PrP [102] a humoral immune response, which 
providing partial protection in animal model of prion diseases was elicited.
Although the protective role of the aforementioned, peptide-based approaches was not inves-
tigated on all occasions, it became evident that using various approaches the self-tolerance 
effects can be overcome and immune reactions against the prion protein can be obtained. 
However, it appears that protection against TSEs is restricted to antibodies capable of 
 recognizing the native cell-surface PrPC [95]. This requirement was met by antibodies known 
to provide protection against TSEs, e.g., ICSM18 [77] and 6H4 [76], whereas other antibodies 
Antibody 
name
Antibody 
type and 
target
Epitope Administration protocol In vitro assay In vivo assay Reference
W226 Monoclonal, 
scFV
Undefined Intraperitoneal 
administration twice 
weekly starting 2 or 28 days 
after administration of the 
pathogen or at onset of the 
clinical symptoms
Clearance of 
PrPSc in ScN2a 
cells
Minor delay of 
incubation time in 
immunized versus 
control mice
[116]
EB8, DC2, 
DE10, 
EF2
Monoclonal EB8: 26–34aa; 
DC2: 35–46aa;
DE10: 44–52aa 
and EF2: 
47–52aa
NP Clearance of 
PrPSc in ScGT2 
cells
NP [117]
Table 1. Summary of studies based on passive immunization against prion diseases.
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capable of recognizing recombinant PrP but unable to provide protection against TSEs also 
failed to recognize native PrPC [72, 95].
4.2.2. DNA vaccines
In addition to peptide-based vaccines, DNA vaccines were also used to promote immune 
responses against the prion protein. In this case, nucleic acid encoding for the prion pro-
tein is administered to animals, wherein the nucleic acid is translated to the corresponding 
protein and an immune response is initiated. The first attempt at raising anti-PrP antibodies 
using DNA vaccines was only successful in PrP−/− mice, whereas the same approach failed 
to give rise to anti-PrP antibodies in wild-type mice [103]. Induction of anti-PrP antibod-
ies using DNA vaccines in wild-type mice was triggered when the mice were immunized 
with a DNA construct coding for the murine prion protein fused to the lysosomal targeting 
signal from lysosomal integral membrane protein type II (LIMPII). Immunization with this 
construct leads to a remarkable delay on the onset of disease symptoms, which was not fol-
lowed by a similar prolongation of survival interval. This discrepancy in the obtained results 
was attributed to immunopathology mediated by PrP-specific antibodies induced by the 
DNA vaccine used and constitutes the first report of adverse effects following active prion 
immunization [104].
In a different approach, DNA vaccines were used to prime wild-type mice, followed by pep-
tide immunizations to further boost immune responses. Although this approach was success-
ful when PrP-/- mice were immunized, very low antibody titers and only marginal protection 
were achieved when tested on wild-type mice [105]. In a recent report, wild-type mice were 
immunized with cDNA coding for human PrPC fused to a T-cell stimulatory peptide. These 
mice developed a strong humoral immune response against the native protein, and although a 
bioassay was not carried out, the produced antibodies were capable of recognizing the native 
conformation of murine PrPC, which—as already mentioned—constitutes a strong indicator 
of protective efficiency against prion diseases [106]. Studies based on DNA vaccines are sum-
marized in Table 3.
4.2.3. Immunization with PrP-displaying viral constructs
A different approach to overcome the tolerance effects and stimulate the production of anti-
PrP antibodies in wild-type mice is the expression of the prion protein on the surface of viral 
particles (summarized in Table 4). Virus-like particles (VLPs) are much better B lymphocytes 
immunogens than monovalent proteins and would be expected to trigger a stronger humoral 
immune response by passing tolerance.
In a first attempt, retroviral particles displaying the C-terminal portion of murine PrP were 
used to immunize wild-type mice. These mice developed anti-PrP antibodies, capable of rec-
ognizing the native form of PrPC, thus displaying strong therapeutic potential [107]. A similar 
approach was used to insert the 9-amino-acid-, prion-pathogenesis associated-peptide pertain-
ing to the murine/rat prion protein into the L1 major capsid protein of bovine  papillomavirus 
type 1. These VLPs were used to immunize both wild-type rats and rabbits. The anti-sera 
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Antigen Animals 
immunized
Humoral response T-cell 
responses
In vitro assays In vivo assays Reference
Various murine 
PrP peptides
Wild-type mice + NP NP Reduction of proteinase 
K-resistant prion 
protein in a scrapie-
infected tumor 
transplant
[93]
Recombinant 
murine PrP 
chemically 
cross-linked to 
bacterial heat-
shock proteins
Wild-type mice + NP NP NP [100]
Recombinant 
murine PrP
Wild-type mice + NP NP Prolongation of 
survival interval in  
a mouse model of 
prion disease
[89]
Recombinant 
murine PrP 
dimer
Wild-type mice, 
rabbits
+ NP Polyclonal 
sera produced 
reduced PrPSc 
synthesis in 
prion-infected 
cell lines
NP [94]
Recombinant 
murine prion 
peptide 105–125 
linked to 
keyhole limpet 
hemocyanin and 
recombinant 
murine prion 
90–230
Wild-type mice + NP NP Prolongation of 
survival interval  
in a mouse model of  
prion disease
[92]
Mouse prion 
peptides 31–50 
and 211–230
Wild-type mice NP NP NP Prolongation of 
survival interval in a 
mouse model of prion 
disease, even when 
only the adjuvant 
Complete Freund’s 
Adjuvant (CFA) is 
administered
[99]
Various murine 
prion peptides 
and adjuvants
Wild-type mice + ND FACS to detect 
binding of 
the produced 
antibodies on 
native PrP
Statistically 
insignificant 
prolongation of 
survival time in a 
mouse model of  
prion disease
[95]
Murine prion 
peptides 39–67, 
98–127, 143–172, 
and 158–187 with 
CFA or CpG
Wild-type mice + + NP NP [98]
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Antigen Animals 
immunized
Humoral response T-cell 
responses
In vitro assays In vivo assays Reference
Hamster prion 
peptides 105–
128, 119–146,  
and 142–179
Wild-type 
hamsters
+ NP NP Prolongation of 
survival interval in a 
hamster model of prion 
diseases
[91]
Recombinant 
murine, ovine, 
and bovine 
prion protein
Wild-type mice Detected following 
immunization with 
ovine and bovine 
recombinant PrP
NP NP Prolongation of 
survival interval in a 
mouse model of prion 
diseases following 
immunization with  
the bovine-recombinant 
protein
[97]
Recombinant 
murine PrP 
dimer and CpG 
encapsulated 
in polylactide-
coglycolide 
microspheres
Wild-type mice + + NP NP [96]
Murine scrapie-
associated 
fibrils and CpG
Transgenic and 
wild-type mice
+ NP NP Prolongation of 
the survival interval of 
the wild-type mice in a 
mouse model of prion 
disease when CpG was 
used
[101]
Murine scrapie-
associated fibrils 
immobilized  
on Dynabeads
Wild-type mice + NP NP Prolongation of 
survival interval in a 
mouse model of prion 
diseases with the 
bovine-recombinant 
protein
[102]
Cervid prion 
peptide 
sequences 
168–182 and 
145–164
Deer + NP NP Delay of incubation 
time in immunized 
versus control mice
[118]
Prion disease-
derived brain 
material
Camelid + NP Permanent 
abrogation 
of prion 
replication in 
a prion-
permissive cell 
line
NP [119]
rPrP aggregates, 
solubilized  
rPrP, DnaK-
fused PrP
Mouse + NP FACS to detect 
binding of 
the produced 
antibodies on 
native PrP
Statistically significant 
prolongation of 
survival time in 
a mouse model  
of prion disease
[72]
Table 2. Summary of studies on peptide-based active immunization against prion diseases.
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Vaccine Immunized 
animals
Humoral 
response
T-cell responses In vitro assays In vivo assays Reference
DNA vaccine 
encoding 
either murine 
PrP or murine 
PrP fused to 
ubiquitin or 
to a lysosomal 
targeting signal
Wild-type mice + + NP Prolongation of 
asymptomatic period 
and accumulation of 
disease associated PrP, 
but not of survival 
interval. Death of 
the immunized mice 
was attributed to 
neurodegeneration 
associated with 
production of anti-PrP 
antbodies
[104]
DNA vaccine 
encoding  
murine PrP 
linked to helper 
T-cell epitopes
Combination 
of DNA 
and peptide 
immunization
PrP−/− and wild-
type mice
Achieved in 
PrP−/− mice, 
very low titer 
in wild-type 
mice
Detected in 
PrP−/− mice but 
not wild-type 
mice
FACS to detect 
binding of 
the produced 
antibodies 
on native PrP 
positive with 
PrP−/− mice sera, 
negative with 
wild-type mice 
sera. PrP−/− mice 
sera reduced 
PrPSc levels in 
prion-infected 
cell lines
Not effective [105]
DNA vaccine 
encoding 
human PrP 
fused or not to 
a tetanus toxin 
stimulatory 
T-cell epitope 
and PrP  
protein boost
Wild-type mice + NP FACS to detect 
binding of 
the produced 
antibodies on 
native PrP
NP [106]
DNA vaccine 
encoding human 
PrP fused to 
ubiquitin, 
lysosomal 
integral 
membrane 
protein type 
II lysosome-
targeting 
signal or an 
ER-targeting 
signal in 
conjunction with 
PrP vaccination
Wild-type mice + + NP NP [120]
Table 3. Summary of studies on DNA vaccination against prion diseases.
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collected from both immunized species recognized native PrPSc, and importantly immune 
serum from the immunized rabbit prevented synthesis of PrPSc in scrapie-infected cell lines 
[108]. In a more recent approach, dendritic cells transduced with adenoviruses encoding the 
human prion protein were used to immunize wild-type mice. These mice developed antibod-
ies against the murine prion protein as well, which provided partial protection against TSEs, 
as shown by the reduction in splenic PrPSc accumulation and prolongation of survival interval 
in a murine model of TSEs [109].
4.2.4. Mucosal immunization
To date, the only active immunization strategy providing complete protection against prion 
diseases is mucosal immunization. To trigger mucosal immunization, either transgenic, live-
attenuated Salmonella typhimurium or cholera toxin is used. Both the attenuated S. typhimurium 
and the cholera toxin induce the production of IgA, which is the main immunoglobulin found 
in mucous secretions and is particularly abundant in the secretions of the gastrointestinal tract.
To induce mucosal immunization, a live-attenuated S. typhimurium vaccine strain engineered 
to express one [110] or two copies [110–112] of mouse [110, 112] or deer [111] PrP was admin-
istered orally to mice and deer, respectively. In a different approach, a murine PrP fragment 
was coadministered with cholera toxin either orally or intranasally [113]. The immunized ani-
mals were then orally challenged with a murine model of TSEs or chronic wasting disease 
(CWD)—infected brain homogenate to evaluate the protective potential of the  immunization. 
Although both approaches promoted the generation of anti-PrP IgA, protection afforded by the 
Vaccine Immunized 
animals
Humoral 
response
T-cell 
responses
In vitro assay In vivo assay Reference
Murine PrP or 
C-terminal murine 
PrP expressed on 
recombinant retroviral 
virus-like particles
PrP−/− and wild-
type mice
+ NP FACS to detect binding 
of the produced 
antibodies on native  
PrP
NP [107]
Murine/rat prion 9/
mer inserted into 
the L1 major capsid 
protein of bovine 
papillomavirus  
type 1
Wild-type rabbits 
and rats
+ NP FACS to detect binding 
of the produced 
antibodies on native PrP, 
immunoprecipitation
Rabbit immune sera 
inhibited de novo 
synthesis of PrPSc in 
prion-infected cells
NP [108]
Priming with 
adenovirus 5 
expressing the human 
PrP gene followed 
by boosting with the 
human PrP plasmid
PrP−/− and wild-
type mice
+ + FACS to detect binding 
of the produced 
antibodies on native  
PrP
Marginal 
prolongation 
of survival 
interval of the 
immunized 
mice
[109]
Table 4. Studies on active immunization approaches, using PrP-displaying virus constructs.
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immunized animals varied greatly. Animals immunized with the attenuated PrP-expressing 
Salmonella survived significantly longer than control animals, and most importantly some of 
them were completely protected, remaining disease-free [110–112]. On the other hand, the 
cholera toxin was used to induce production of IgA, mice were only partially protected against 
oral exposure to the infectious agent, and modest prolongation of the survival interval was 
observed, without any mice remaining symptoms-free [113]. Studies dealing with mucosal 
immunization are summarized in Table 5.
Although mucosal immunization is only effective following oral exposure, it is important 
to remember that the gut is the major route of entry for prion diseases such as CWD in 
white-tailed deer, BSE in cattle, and variant Creutzfeldt-Jakob disease and kuru in humans. 
Furthermore, mucosal vaccination can be properly designed to induce a primarily humoral 
immune response and is unlikely to produce a significant immune response within the brain, 
thus minimizing the risk of appearance of adverse reactions [112].
5. Future perspectives
Despite fervent research and some very encouraging results, many facets of the involvement 
of the immune system in prion pathogenesis remain obscure, and a powerful immunoprotec-
tive tool has yet to emerge. Passive immunization with anti-prion antibodies and mucosal 
immunization were the only two approaches to provide satisfactory results but have a series 
of limitations associated with the narrow window of intervention and the route of infection. 
However, immune-based therapeutics both in their more classical immunization-based form 
or more modern, immunomodulatory form [114] hold great promise for prion diseases and 
other protein-misfolding diseases.
Vaccine Immunized 
animals
Humoral 
response
T-cell 
responses
In vitro 
assay
In vivo assay Reference
Orally administered 
S. typhimurium LVR01 
expressing one or two 
copies of mouse PrP
Wild-type mice + NP NP Significant prolongation  
of survival interval in a 
mouse model of prion 
disease
[110, 112]
Intranasally, 
intragastrically, or 
intraperitoneally 
administered murine 
PrP90–231 and cholera 
toxin
Wild-type mice + NP NP Marginal prolongation 
of survival interval 
in a mouse model of 
prion disease following 
intranasal administration
[113]
Orally administered 
S. typhimurium LVR01 
expressing two copies  
of elk PrP
White-tailed 
deers
+ NP NP Significant prolongation 
of survival interval in an 
elk model of prion disease. 
One immunized animal 
remained asymptomatic
[111]
Table 5. Mucosal vaccination approaches.
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